Goel S - Search Results

1

Swami U, Shah U, Goel S. Swami U, et al. Among authors: goel s. Mar Drugs. 2015 Aug 7;13(8):5016-58. doi: 10.3390/md13085016. Mar Drugs. 2015. PMID: 26262627 Free PMC article. Review.

2

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH. Goel S, et al. Clin Cancer Res. 2009 Jun 15;15(12):4207-12. doi: 10.1158/1078-0432.CCR-08-2429. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509177 Clinical Trial.

3

Eribulin -- a review of preclinical and clinical studies.

Swami U, Chaudhary I, Ghalib MH, Goel S. Swami U, et al. Among authors: goel s. Crit Rev Oncol Hematol. 2012 Feb;81(2):163-84. doi: 10.1016/j.critrevonc.2011.03.002. Epub 2011 Apr 14. Crit Rev Oncol Hematol. 2012. PMID: 21493087 Free PMC article. Review.

4

Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.

Aparo S, Goel S. Aparo S, et al. Among authors: goel s. Crit Rev Oncol Hematol. 2012 Jul;83(1):47-58. doi: 10.1016/j.critrevonc.2011.08.006. Epub 2011 Sep 23. Crit Rev Oncol Hematol. 2012. PMID: 21944740 Free PMC article. Review.

5

Carfilzomib for the treatment of multiple myeloma.

Lue J, Goel S, Mazumder A. Lue J, et al. Among authors: goel s. Drugs Today (Barc). 2013 Mar;49(3):171-9. doi: 10.1358/dot.2013.49.3.1939264. Drugs Today (Barc). 2013. PMID: 23527321

6

Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Swami U, Goel S, Mani S. Swami U, et al. Among authors: goel s. Curr Drug Targets. 2013 Jun;14(7):777-97. doi: 10.2174/1389450111314070007. Curr Drug Targets. 2013. PMID: 23597015 Free PMC article. Review.

7

Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010.

Hou JY, Aparo S, Ghalib M, Chaudhary I, Shah U, Swami U, Einstein M, Goldberg GL, Mani S, Goel S. Hou JY, et al. Among authors: goel s. Gynecol Oncol. 2013 Oct;131(1):163-8. doi: 10.1016/j.ygyno.2013.07.089. Epub 2013 Jul 19. Gynecol Oncol. 2013. PMID: 23877015 Clinical Trial.

8

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.

Tan AR, Sarantopoulos J, Lee L, Reyderman L, He Y, Olivo M, Goel S. Tan AR, et al. Among authors: goel s. Cancer Chemother Pharmacol. 2015 Nov;76(5):1051-61. doi: 10.1007/s00280-015-2878-5. Epub 2015 Oct 3. Cancer Chemother Pharmacol. 2015. PMID: 26433580 Free PMC article. Clinical Trial.

9

Eribulin in non-small cell lung cancer: challenges and potential strategies.

Swami U, Shah U, Goel S. Swami U, et al. Among authors: goel s. Expert Opin Investig Drugs. 2017 Apr;26(4):495-508. doi: 10.1080/13543784.2017.1292250. Epub 2017 Feb 22. Expert Opin Investig Drugs. 2017. PMID: 28161993 Review.

10

Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer.

Goel S, Negassa A, Khot A, Goyal D, Guo S, Nandikolla A, Bakirhan K, Polineni R, Shah U, Chaudhary I, Ghalib MH, Rajdev L, Kaubisch A, Chuy J, Aparo S. Goel S, et al. Clin Colorectal Cancer. 2017 Dec;16(4):286-292. doi: 10.1016/j.clcc.2017.03.004. Epub 2017 Mar 14. Clin Colorectal Cancer. 2017. PMID: 28412139

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,801 results

Search Page